Showing papers by "Horst Lindhofer published in 2008"

Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 × anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels

Abstract: Trifunctional bispecific antibodies can efficiently mediate tumor cell killing by redirecting T cells and immune accessory cells to the tumor cell. Here, we describe the new trifunctional antibody, Bi20 (FBTA05, anti-CD20 x anti-CD3), that connects B cells and T cells via its variable regions and recruits FcgammaRI(+) accessory immune cells via its Fc region. Bi20 mediated efficient and specific lysis of B-cell lines and of B cells with low CD20 expression levels that were derived from CLL patients. Remarkably, T-cell activation and tumor cell killing occurred in an entirely autologous setting without additional effector cells in 5 of 8 samples. In comparison, rituximab, a chimeric monoclonal CD20 antibody, demonstrated a significantly lower B-cell eradication rate. Additionally, Bi20, but not rituximab, upregulated the activation markers CD25 and CD69 on both CD4(+) and CD8(+) T cells in the presence of accessory immune cells. CD14(+) accessory cells and the monocyte cell line THP-1 were activated via binding of the Fc region of Bi20, given that T cells were simultaneously engaged by the antibody. Bi20 induced a strong Th1 cytokine pattern characterized by high IFN-gamma and very low IL-4 secretion. In conclusion, Bi20 may offer new immunotherapeutic options for the treatment of B-cell lymphomas.

Intraoperative trifunctional antibody application for prophylaxis of intraperitoneal tumor cell dissemination

Abstract: The invention describes the use of trifunctional bispecific and trispecific antibodies for destroying tumor cells which e.g. are disseminated intraperitoneally due to a surgical intervention, wherein the antibody is administered intraoperatively, preferably directly locally into the abdominal cavity.

Pharmacokinetics and in vivo stability of intraperitoneally administered therapeutic antibody catumaxomab

Abstract: 14006 Background: The EpCAM-specific trifunctional rat/mouse hybrid antibody catumaxomab simultaneously activates T cells and Fcγ-receptor positive immune cells redirecting them against the tumor. ...

Intraoperative, adjuvant treatment of gastric cancer with the trifunctional antibody catumaxomab compared to surgery alone: A phase II study

Abstract: 15529 Background: Gastric cancer patients (pts) have a high risk of peritoneal recurrence due to disseminated tumor cells after surgery. The trifunctional antibody catumaxomab (anti-EpCAM × anti-CD...

Effect on low HER2 (1+) expressing tumor cells of the trifunctional antibody ertumaxomab

Abstract: 3071 Background: Her2/neu has become an important therapeutic target for treatment of breast cancer with overexpressed Her2/neu. Currently, no approved antibody-based therapy is available for breas...

Intraoperative trifunktionale antikörper-applikation zur prophylaxe intraperitonealer tumorzelldissemination

Abstract: Die Erfindung beschreibt die Verwendung trifunktioneller bispezifischer und trispezifischer Antikorper zur Zerstorung von Tumorzellen, die z. B. durch einen chirurgischen Eingriff intraperitoneal disseminiert werden, wobei der Antikorper intraoperativ, bevorzugt direkt lokal in die Bauchhohle, verabreicht wird.